Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
- PMID: 17202311
- DOI: 10.1158/1078-0432.CCR-06-0267
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
Abstract
Purpose: Somatic mutations of PIK3CA, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase, have recently been shown to play an important role in the pathogenesis and progression of human breast cancers. In this study, the frequency of PIK3CA mutations and their relationship with clinicopathologic and biological variables were investigated in Japanese breast cancers.
Experimental design: Mutational analysis of PIK3CA was done in 188 primary breast cancers of Japanese women. Relationship of these mutations with various clinicopathologic variables [histologic type, tumor size, histologic grade, lymph node status, estrogen receptor (ER)-alpha and progesterone receptor status, and prognosis], biological variables [phospho-AKT (pAKT) and HER2 expression determined by immunohistochemistry], and p53 mutation status was studied.
Results: Missense mutations of PIK3CA were found in 44 of 158 invasive ductal carcinomas, 4 of 10 invasive lobular carcinomas, 1 of 4 mucinous carcinomas, 2 of 2 squamous carcinomas, and 2 of 2 apocrine carcinomas, but no mutation was found in 12 noninvasive ductal carcinomas. PIK3CA-mutated tumors were found to be more likely to be ER-alpha positive (P < 0.05) and pAKT positive (P < 0.05). There was no significant association between PIK3CA mutations and p53 mutation status. PIK3CA mutations were significantly (P < 0.05) associated with a favorable prognosis, and multivariate analysis showed that PIK3CA mutation status was a significant (P < 0.05) prognostic factor independent of the other conventional prognostic factors.
Conclusions: The frequency of PIK3CA mutations in Japanese breast cancers is similar to that of Caucasian breast cancers. Association of PIK3CA mutations with positive pAKT and positive ER-alpha suggests that PIK3CA mutations might exert their effects through activation of the phosphatidylinositol 3-kinase/AKT/ER-alpha pathway. PIK3CA mutations seem to have a potential to be used as an indicator of favorable prognosis.
Similar articles
-
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.Exp Mol Pathol. 2010 Feb;88(1):150-5. doi: 10.1016/j.yexmp.2009.09.016. Epub 2009 Oct 8. Exp Mol Pathol. 2010. PMID: 19818761
-
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.J Pathol. 2006 Feb;208(3):350-5. doi: 10.1002/path.1908. J Pathol. 2006. PMID: 16353168
-
PIK3CA mutations in breast cancer are associated with poor outcome.Breast Cancer Res Treat. 2006 Mar;96(1):91-5. doi: 10.1007/s10549-005-9048-0. Epub 2005 Nov 30. Breast Cancer Res Treat. 2006. PMID: 16317585
-
Oncogenic PI3K deregulates transcription and translation.Nat Rev Cancer. 2005 Dec;5(12):921-9. doi: 10.1038/nrc1753. Nat Rev Cancer. 2005. PMID: 16341083 Review.
-
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.Cancer Med. 2020 Sep;9(18):6463-6472. doi: 10.1002/cam4.3278. Epub 2020 Jul 22. Cancer Med. 2020. PMID: 32697890 Free PMC article. Review.
Cited by
-
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Nat Rev Clin Oncol. 2012 Sep;9(9):529-41. doi: 10.1038/nrclinonc.2012.121. Epub 2012 Jul 24. Nat Rev Clin Oncol. 2012. PMID: 22825374 Review.
-
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.Virchows Arch. 2010 Mar;456(3):235-43. doi: 10.1007/s00428-010-0881-0. Epub 2010 Feb 4. Virchows Arch. 2010. PMID: 20130907
-
Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001).Mol Clin Oncol. 2013 Jan;1(1):47-52. doi: 10.3892/mco.2012.10. Epub 2012 Aug 9. Mol Clin Oncol. 2013. PMID: 24649121 Free PMC article.
-
Membrane lipids in invadopodia and podosomes: key structures for cancer invasion and metastasis.Oncotarget. 2010 Sep;1(5):320-328. doi: 10.18632/oncotarget.164. Oncotarget. 2010. PMID: 21307399 Free PMC article. Review.
-
Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor.Animals (Basel). 2021 Jul 12;11(7):2079. doi: 10.3390/ani11072079. Animals (Basel). 2021. PMID: 34359206 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous